<table id="t6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6          Established and Other Potentially Significant<footnote>This table is not all inclusive.</footnote> Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction </caption>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="60%"></col>
<thead>
<tr valign="middle">
<th align="center" stylecode="Lrule Rrule">Concomitant Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule">Effect on Concentration<footnote>   ↑ = Increase, ↓ = Decrease, ⇔ = No Effect</footnote>
</th>
<th align="center" stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Acid Reducing Agents:</content>
<br/>Antacids<footnote id="ft6.1">Indicates that a drug-drug interaction trial was conducted.</footnote> (for example aluminum and magnesium hydroxide)</td>
<td stylecode="Rrule">↓ elvitegravir</td>
<td stylecode="Rrule">Separate STRIBILD and antacid administration by at least 2 hours.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>e.g.,<br/>amiodarone<br/>bepridil<br/>digoxin<footnoteref idref="ft6.1"></footnoteref>
<br/>disopyramide<br/>flecainide<br/>systemic lidocaine mexiletine<br/>propafenone<br/>quinidine</td>
<td stylecode="Rrule Toprule">↑ antiarrhythmics<br/>↑ digoxin</td>
<td stylecode="Rrule Toprule">Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antibacterials:</content>
<br/>clarithromycin</td>
<td stylecode="Rrule">↑ clarithromycin<br/>↑ cobicistat</td>
<td stylecode="Rrule">
<content stylecode="underline">Patients with CLcr greater than or equal to 60 mL/minute: </content>
<br/>No dose adjustment of clarithromycin is required.<br/>
<content stylecode="underline">Patients with CLcr between 50 mL/minute and 60 mL/minute: </content>
<br/>The dose of clarithromycin should be reduced by 50%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulants:</content>
<br/>warfarin</td>
<td stylecode="Rrule">Effect on warfarin unknown</td>
<td stylecode="Rrule">Monitor international normalized ratio (INR) upon coadministration of warfarin with STRIBILD.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>oxcarbazepine </td>
<td stylecode="Rrule">↓ elvitegravir<br/>↓ cobicistat</td>
<td stylecode="Rrule">Alternative anticonvulsants should be considered when STRIBILD is coadministered with oxcarbazepine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">clonazepam<br/>ethosuximide</td>
<td stylecode="Rrule">↑ clonazepam<br/>↑ ethosuximide</td>
<td stylecode="Rrule"> Clinical monitoring is recommended upon coadministration of clonazepam or ethosuximide with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antidepressants:</content>
<br/>Selective Serotonin Reuptake Inhibitors (SSRIs)<br/>e.g.,<br/>paroxetine<br/>
<br/>Tricyclic<br/>Antidepressants (TCAs)<br/>e.g.,<br/>amitriptyline<br/>desipramine<br/>imipramine<br/>nortriptyline<br/>bupropion<br/>trazodone</td>
<td stylecode="Rrule">↑ SSRIs<br/>↑ TCAs<br/>↑ trazodone</td>
<td stylecode="Rrule">Careful dose titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungals</content>:<br/>itraconazole ketoconazole<footnoteref idref="ft6.1"></footnoteref>
<br/>voriconazole</td>
<td stylecode="Rrule">↑ elvitegravir<br/>↑ cobicistat<br/>↑ itraconazole<br/>↑ ketoconazole<br/>↑voriconazole</td>
<td stylecode="Rrule">When coadministered with STRIBILD, the maximum daily dose of ketoconazole or itraconazole should not exceed 200 mg per day.<br/>An assessment of benefit/risk ratio is recommended to justify use of voriconazole with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-gout:</content>
<br/>colchicine</td>
<td stylecode="Rrule">↑ colchicine</td>
<td stylecode="Rrule">STRIBILD is not recommended to be  coadministered with colchicine to patients with renal or hepatic impairment.<br/>
<content stylecode="underline">Treatment of gout-flares – coadministration of colchicine in patients receiving STRIBILD:</content>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.<br/>
<content stylecode="underline">Prophylaxis of gout-flares – coadministration of colchicine in patients receiving STRIBILD:</content>
<br/>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<content stylecode="underline">Treatment of familial Mediterranean fever – coadministration of colchicine in patients receiving STRIBILD:</content>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterial:</content>
<br/>rifabutin<footnoteref idref="ft6.1"></footnoteref>
<br/>rifapentine</td>
<td stylecode="Rrule">↓ elvitegravir<br/>↓ cobicistat</td>
<td stylecode="Rrule">Coadministration of STRIBILD with rifabutin or rifapentine is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Beta-Blockers:</content>
<br/>e.g.,<br/>metoprolol<br/>timolol</td>
<td stylecode="Rrule">↑ beta-blockers</td>
<td stylecode="Rrule">Clinical monitoring is recommended and a dose decrease of the beta blocker may be necessary when these agents are coadministered with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium Channel Blockers:</content>
<br/>e.g., amlodipine<br/>diltiazem<br/>felodipine<br/>nicardipine<br/>nifedipine<br/>verapamil</td>
<td stylecode="Rrule">↑ calcium channel blockers</td>
<td stylecode="Rrule">Caution is warranted and clinical monitoring is recommended upon coadministration of calcium channel blockers with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid:<br/>Systemic:</content>
<br/>dexamethasone</td>
<td stylecode="Rrule">↓ elvitegravir<br/>↓ cobicistat</td>
<td stylecode="Rrule">Alternative corticosteroids should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid:<br/>Inhaled/Nasal:</content>
<br/>fluticasone</td>
<td stylecode="Rrule">↑ fluticasone</td>
<td stylecode="Rrule">Concomitant use of STRIBILD with inhaled or nasal fluticasone may reduce serum cortisol concentrations. Alternative corticosteroids should be considered, particularly for long term use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Endothelin Receptor Antagonists:</content>
<br/>bosentan</td>
<td stylecode="Rrule">↑ bosentan</td>
<td stylecode="Rrule">
<content stylecode="underline">Coadministration of bosentan in patients on  STRIBILD:</content>
<br/>In patients who have been receiving STRIBILD for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<content stylecode="underline">Coadministration of STRIBILD in patients on bosentan:</content>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of STRIBILD. After at least 10 days following the initiation of STRIBILD, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA Reductase Inhibitors:</content>
<br/>atorvastatin</td>
<td stylecode="Rrule">↑ atorvastatin</td>
<td stylecode="Rrule">Initiate with the lowest starting dose of atorvastatin and titrate carefully while monitoring for safety.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hormonal Contraceptives:</content>
<br/>norgestimate/ethinyl estradiol<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Rrule">↑ norgestimate<br/>↓ ethinyl estradiol</td>
<td stylecode="Rrule">The effects of increases in the concentration of the progestational component norgestimate are not fully known and can include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis. The potential risks and benefits associated with coadministration of norgestimate/ethinyl estradiol with STRIBILD should be considered, particularly in women who have risk factors for these events.<br/>Coadministration of STRIBILD with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives) or oral contraceptives containing progestogens other than norgestimate has not been studied; therefore, alternative (non-hormonal) methods of contraception can be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immuno-suppressants:</content>
<br/>e.g.,<br/>cyclosporine<br/>sirolimus<br/>tacrolimus</td>
<td stylecode="Rrule">↑ immuno-suppressants</td>
<td stylecode="Rrule">Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesics: </content>
<br/>buprenorphine/<br/>naloxone<footnoteref idref="ft6.1"></footnoteref>
</td>
<td stylecode="Rrule">
<br/>↑ buprenorphine<br/>↑ norbuprenorphine<br/>↓ naloxone</td>
<td stylecode="Rrule">No dose adjustment of buprenorphine/naloxone is required upon coadministration with STRIBILD. Patients should be closely monitored for sedation and cognitive effects.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled Beta Agonist:</content>
<br/>salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Coadministration of salmeterol and STRIBILD is not recommended because it may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Neuroleptics</content>:<br/>e.g.,<br/>perphenazine<br/>risperidone<br/>thioridazine</td>
<td stylecode="Rrule">↑ neuroleptics</td>
<td stylecode="Rrule">A decrease in dose of the neuroleptic may be needed when coadministered with STRIBILD.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Phosphodiesterase-5 (PDE-5) Inhibitors: </content>
<br/>sildenafil<br/>tadalafil<br/>vardenafil</td>
<td stylecode="Rrule">↑ PDE-5 inhibitors</td>
<td stylecode="Rrule">Coadministration with STRIBILD may result in an increase in PDE-5 inhibitor associated adverse reactions, including hypotension, syncope, visual disturbances, and priapism.<br/>
<content stylecode="underline">Use of tadalafil for pulmonary arterial hypertension (PAH):</content>
<list listtype="unordered">
<item>
<content stylecode="italics">Coadministration of tadalafil in patients on STRIBILD:</content>
<list listtype="unordered">
<item>
<caption> </caption>In patients receiving STRIBILD for at least 1 week, start tadalafil at 20 mg once daily. Increase tadalafil dose to 40 mg once daily based upon individual tolerability.</item>
</list>
</item>
<item>
<content stylecode="italics">Coadministration of STRIBILD in patients on tadalafil:</content>
<list listtype="unordered">
<item>
<caption> </caption>Avoid use of tadalafil during the initiation of STRIBILD. Stop tadalafil at least 24 hours prior to starting STRIBILD. After at least one week following initiation of STRIBILD, resume tadalafil at 20 mg once daily. Increase tadalafil dose to 40 mg once daily based upon individual tolerability.</item>
</list>
</item>
</list>
<content stylecode="underline">Use of PDE-5 inhibitors for erectile dysfunction:</content>
<br/>The below PDE-5 inhibitors can be used along with increased monitoring for PDE-5 inhibitor associated with adverse events: 															<list listtype="unordered">
<item>Sildenafil at a single dose not exceeding 25 mg in 48 hours or,</item>
<item>Tadalafil at a single dose not exceeding 10 mg in 72 hours, or</item>
<item>Vardenafil at a single dose not exceeding 2.5 mg in 72 hours</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Sedative/hypnotics:</content>
<br/>Benzodiazepines:<br/>e.g.,<br/>Parenterally administered  midazolam<br/>clorazepate<br/>diazepam<br/>estazolam<br/>flurazepam<br/>buspirone<br/>zolpidem</td>
<td stylecode="Rrule">↑ sedatives/hypnotics</td>
<td stylecode="Rrule">Coadministration of parenteral midazolam with STRIBILD should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.<br/>With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.</td>
</tr>
</tbody>
</table>